CYP17 inhibitors for prostate cancer therapy
- 31 May 2011
- journal article
- review article
- Published by Elsevier BV in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 125 (1-2), 23-31
- https://doi.org/10.1016/j.jsbmb.2010.11.005
Abstract
No abstract availableKeywords
This publication has 91 references indexed in Scilit:
- CYP24A1 Inhibition Enhances the Antitumor Activity of CalcitriolEndocrinology, 2010
- A Phase I Clinical Study of High Dose Ketoconazole Plus Weekly Docetaxel for Metastatic Castration Resistant Prostate CancerJournal of Urology, 2010
- Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2010
- Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone AcetateJournal of Clinical Oncology, 2010
- Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole TherapyJournal of Clinical Oncology, 2010
- Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate CancerClinical Cancer Research, 2009
- Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancerMolecular Cancer Therapeutics, 2008
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor GrowthCancer Research, 2008
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003
- 16-Unsaturated C19 steroids a review of their chemistry, biochemistry and possible physiological roleJournal of Steroid Biochemistry, 1972